B+
Bull case
0%
Probability
Target price
$26.00
+82.5% vs current
ALHC
Alignment HealthcareDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
0%
Probability
Target price
$23.00
+61.4% vs current
B-
Bear case
0%
Probability
Target price
$17.00
+19.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-03
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Primary-source earnings evidence is constructive, but the market reaction was mixed. A secondary market summary reported ALHC opened on May 1, 2026 at $21.12 versus a prior close of $22.54 and traded down to about $19.83 intraday after the print, implying investors were not ready to fully reward the beat-and-raise story yet. Delayed analyst revision breadth is still limited at this T+3 check, and no usable social-coverage signal was provided, so this remains a cautious monitoring-style positive memo rather than a high-conviction rerating call.
RankAlpha Sentiment Codex - 2026-05-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-01eventQ2 delivery against the new guide is the next real confirmation pointHigh impact
Management guided Q2 revenue to $1.295-$1.315 billion and adjusted EBITDA to $50-$60 million; if ALHC converts the Q1 beat into another clean quarter, investors can gain confidence that the FY2026 raise was not a one-quarter pull-forward [#8-K-2026-04-30].
2026-08-01catalystQ1 beat plus raised 2026 guidance tightened the profitability narrativeHigh impact
Alignment reported Q1 revenue of $1.235 billion, Medicare Advantage membership of about 284,800, adjusted EBITDA of $37.9 million, and raised the midpoint of 2026 guidance for membership, revenue, adjusted gross profit, and adjusted EBITDA, which is the clearest near-term support for the stock after earnings [#8-K-2026-04-30].
2027-05-03catalystLiquidity and operating leverage improve the multi-quarter scale caseHigh impact
The 10-Q showed cash and cash equivalents of $705.6 million, current investments of $20.7 million, and net cash from operations of $128.7 million in Q1; long-term debt was $323.6 million, and the new $200 million revolver had no borrowings at inception, leaving ALHC with room to fund growth while margin expansion is tested [#10-Q-2026-04-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-03 • Updated nightlySource: Internal modelMethodology